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Abstract
Epstein-Barr virus (EBV) epigenetically reprogrammes B-lymphocytes to drive immortalization and facilitate viral persistence.
Host-cell transcription is perturbed principally through the actions of EBV EBNA 2, 3A, 3B and 3C, with cellular genes
deregulated by specific combinations of these EBNAs through unknown mechanisms. Comparing human genome binding
by these viral transcription factors, we discovered that 25% of binding sites were shared by EBNA 2 and the EBNA 3s and
were located predominantly in enhancers. Moreover, 80% of potential EBNA 3A, 3B or 3C target genes were also targeted by
EBNA 2, implicating extensive interplay between EBNA 2 and 3 proteins in cellular reprogramming. Investigating shared
enhancer sites neighbouring two new targets (WEE1 and CTBP2) we discovered that EBNA 3 proteins repress transcription
by modulating enhancer-promoter loop formation to establish repressive chromatin hubs or prevent assembly of active
hubs. Re-ChIP analysis revealed that EBNA 2 and 3 proteins do not bind simultaneously at shared sites but compete for
binding thereby modulating enhancer-promoter interactions. At an EBNA 3-only intergenic enhancer site between ADAM28
and ADAMDEC1 EBNA 3C was also able to independently direct epigenetic repression of both genes through enhancer-
promoter looping. Significantly, studying shared or unique EBNA 3 binding sites at WEE1, CTBP2, ITGAL (LFA-1 alpha chain),
BCL2L11 (Bim) and the ADAMs, we also discovered that different sets of EBNA 3 proteins bind regulatory elements in a gene
and cell-type specific manner. Binding profiles correlated with the effects of individual EBNA 3 proteins on the expression of
these genes, providing a molecular basis for the targeting of different sets of cellular genes by the EBNA 3s. Our results
therefore highlight the influence of the genomic and cellular context in determining the specificity of gene deregulation by
EBV and provide a paradigm for host-cell reprogramming through modulation of enhancer-promoter interactions by viral
transcription factors.
Citation: McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, et al. (2013) Modulation of Enhancer Looping and Differential Gene Targeting by Epstein-Barr
Virus Transcription Factors Directs Cellular Reprogramming. PLoS Pathog 9(9): e1003636. doi:10.1371/journal.ppat.1003636
Editor: Paul M. Lieberman, Wistar Institute, United States of America
Received March 24, 2013; Accepted August 3, 2013; Published September 12, 2013
Copyright:  2013 McClellan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Wellcome Trust (088140) and Leukaemia Lymphoma Research (12035) to MJW. MJM was supported by a
PhD studentship from the Biotechnology and Biological Sciences Research Council. RDP was funded by PhD studentship from the University of Sussex. RGJ was
supported by a Medical Research Council Career Development Award and ASK by an MRC Centre grant to the MRC Centre for Medical Molecular Virology. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: M.J.West@sussex.ac.uk
¤a Current address: School of Biosciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
¤b Current address: London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Introduction
Epstein-Barr virus (EBV) was discovered in cells cultured from a
Burkitt’s lymphoma (BL) biopsy in 1964 [1] and has since been
associated with the development of numerous cancers including
Hodgkin’s disease, post-transplant lymphoma, certain natural
killer and T-cell lymphomas and the epithelial cell tumour
nasopharyngeal carcinoma. EBV immortalizes host B lymphocytes
generating latently infected lymphoblastoid cell lines (LCLs) that
proliferate indefinitely in culture. LCLs express 9 viral latent
proteins: six Epstein-Barr nuclear antigens (EBNAs) and three
latent membrane proteins (LMPs). All EBNAs possess transcrip-
tional regulatory functions and EBNA 2 and the EBNA 3 family of
proteins (3A, 3B and 3C) function as key regulators of viral and
cellular transcription in immortalized cells.
EBNA 2 is essential for initial B-cell immortalization by EBV
and for the continuous growth of EBV transformed cell lines [2–
3]. EBNA 2 functions as the master controller of latent viral gene
transcription and activates the EBV C promoter that drives
production of the long pre-mRNA encoding all EBNAs, in
addition to the promoters of the LMP genes [4–7]. EBNA 2 also
activates transcription of numerous cellular genes involved in
growth control and B-cell activation including MYC, RUNX3,
CD23, CD21 and FGR [8–11]. EBNA 2 cannot bind DNA directly
and interacts with target genes via cellular transcription factors
that include RBP-Jk (C promoter binding factor 1, CBF1) and
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PU.1 (Spi-1) [12–15]. ATF-2/c-Jun heterodimers and EBF1 have
also been implicated in EBNA 2 activation of the EBV LMP1
promoter [16–17] and AUF1 was identified as the CBF2 factor
required for efficient activation of the EBV C promoter [18].
EBNA 2 mediates transcriptional activation through an acidic
activation domain [19–20] and interacts with a number of general
transcription factors including TFIIB, TAF40, the TFIIH p62 and
p80 subunits and a TFIIE–associated protein [21–23]. Transcrip-
tional activation by EBNA 2 is also mediated through association
with histone acetyltransferases [24] and chromatin remodelling
complexes [25–26]. An additional EBNA, EBNA-leader protein
(EBNA-LP) plays a role in augmenting transcriptional activation
by EBNA 2. Expression of EBNA-LP enhances EBNA 2-induced
activation of the viral LMP1 promoter via RBP-Jk sites and EBNA
2 and EBNA-LP cooperate to induce cyclin D2 expression in
resting B-cells [27–29]. EBNA-LP coactivation may be mediated
through relocalization of histone deacetylases from EBNA 2
activated promoters [30].
The genes encoding the EBNA 3 family of transcriptional
regulators (3A, 3B and 3C) probably arose as a result of gene
duplication, since they are tandemly arranged in the EBV genome,
consist of a short 59 and long 39 exon and display an albeit low
degree of amino-acid identity. EBNA 3A and 3C were shown to be
required for immortalization of B-cells by EBV [31], although
more recently short-lived EBV-infected cell lines have been
generated from EBNA 3A knock-out viruses [32]. These data,
combined with studies using cell lines infected with viruses
expressing conditionally active forms of EBNA 3A or 3C, indicate
that the continued proliferation of immortalized cells is dependent
on 3A and 3C function [33–34]. EBNA 3B however, is not
essential for in vitro immortalization [35] but confers a tumour
suppressive function in vivo [36].
Gene expression analysis demonstrates that EBNA 3A, 3B and
3C function as both activators and repressors of cellular gene
expression and transcriptional repression and activation domains
of EBNA 3C have been identified using Gal4-fusion protein
assays [32,37–41]. A well-documented repressive function of the
EBNA 3 proteins involves the inhibition of EBNA 2 activation
through association with the EBNA 2 targeting partner RBP-Jk.
All EBNA 3 proteins can bind RBP-Jk and inhibit EBNA 2
activation via RBP-Jk sites in reporter assays, although loss of
EBNA 3A and 3C function does not increase EBNA 2 activation
of some key target promoters containing RBP-Jk sites in infected
cells [33–34,42–44]. In addition to RBP-Jk, EBNA 3C also binds
to the PU.1 transcription factor implicated in EBNA 2 activation
of the viral LMP1 promoter [45]. In fact EBNA 3C is able to
coactivate the LMP1 promoter with EBNA 2 in a manner
dependent on the PU.1 binding motif [45]. Transcriptional
repression by EBNA 3A and 3C can also be mediated through
interactions with, or recruitment of, multiple transcriptional co-
repressors including C-terminal binding protein (CtBP), histone
deacetylases and polycomb repressor complexes [46–50]. EBNA
3C also associates with the histone acetyltransferase p300,
implicating histone acetylation in EBNA 3C-mediated transcrip-
tional activation [51].
Interestingly, gene expression profiling reveals extensive
overlap in the cellular genes regulated by EBNA 3 proteins
[37–38]. Roughly half of the genes affected by the loss of an
individual EBNA 3 protein in studies using EBV-negative BL cell
lines infected with recombinant knock-out EBVs were also found
to be deregulated in the absence of another EBNA 3 family
member [38]. Co-operative gene regulation by the EBNA 3s is
exemplified in the regulation of genes encoding two key
regulators of immortalized cell growth/survival, the pro-apoptot-
ic protein Bim (BCL2L11) and the cyclin-dependent kinase
inhibitor p16INK4A (CDKN2A) [52–55]. These genes are repressed
through the concerted actions of EBNA 3A and 3C via the
polycomb-associated trimethylation of lysine 27 on histone H3
[48,53,55]. Overlap in cellular gene regulation between EBNA 3
proteins and EBNA 2 is also evident. For example, a recent study
found that 25% of EBNA 3A-regulated genes identified in LCLs
generated from EBNA 3A mutant viruses were also regulated by
EBNA 2, in either a co-operative (9%) or antagonistic manner
(16%) [32]. Moreover, when we compared the EBNA 3C-
regulated genes identified in our own microarray analysis [37]
with genes identified in five EBNA 2 gene expression arrays
[11,56–59], we found that 27% of genes were also regulated by
EBNA 2. Despite the identification of significant numbers of
cellular genes regulated by EBNA 2, 3A, 3B and 3C, the
mechanism through which the majority of these genes are
targeted and epigenetically reprogrammed remains unclear.
Interestingly, our own ChIP-sequencing analysis of human
genome binding by the EBNA 3s and analysis of EBNA 2
binding by Zhao and colleagues has highlighted a role for long-
range enhancer elements in cellular gene deregulation by these
EBV transcription factors [17,37].
We set out to investigate the mechanism of cooperative
cellular gene deregulation by EBNA 2, 3A, 3B and 3C and the
role of long-range enhancers in host-cell reprogramming by
EBV. Significantly, studying regulation via long-range regula-
tory elements we found that EBNA 3 proteins repress cellular
gene transcription by modulating the formation of chromatin
loops between enhancers and promoters. Importantly, our
studies also determined that gene control by different members
of the EBNA 3 transcription factor family is mediated by gene
and cell-type specific binding of subsets of these factors. Our
studies therefore indicate that transcriptional reprogramming by
EBV can be gene and host-cell-specific and involves exploita-
tion and modulation of the three-dimensional chromatin
architecture connecting long-range enhancers with gene pro-
moters.
Author Summary
Epstein-Barr virus (EBV) is associated with numerous
cancers. The ability of the virus to infect B-cells and
convert them from short-lived into immortal cells is the
key to its cancer-promoting properties. A small number of
EBV transcription factors are required for immortalization
and act in concert to drive cell growth by deregulating the
expression of cellular genes through largely unknown
mechanisms. We have demonstrated that four of these key
transcription factors function cooperatively by targeting
common genes via long-range enhancer elements and
modulating their looping interactions with gene promot-
ers. Specifically we show that gene repression by the EBV
EBNA 3 family of proteins can be mediated through the
modulation of enhancer-promoter looping. Our results
also reveal that different subsets of EBNA 3 proteins are
bound at different genes and that this differential binding
can vary in lymphoma cells compared to cells immortal-
ized in culture, indicating that cell-background-specific
gene regulation may be important in lymphoma develop-
ment. Our results demonstrate how cellular genes can be
deregulated by an oncogenic virus through modulation of
enhancer-promoter looping with the specificity of binding
by viral transcription factors controlling cellular repro-
gramming in a gene and cell-type specific manner.
EBV Transcription Factors Control Enhancer Looping
PLOS Pathogens | www.plospathogens.org 2 September 2013 | Volume 9 | Issue 9 | e1003636
Results
EBNA 2 and 3 proteins target common sites and genes
To examine the mechanism of interplay in cellular gene
reprogramming by EBNA 2, 3A, 3B and 3C proteins, we
performed comparative analysis of the human genome regulatory
elements targeted by these factors in a BL cell line expressing all
EBV latent proteins (Mutu III) ([60] and Figure S1). Since EBNA
2 and 3 proteins do not possess direct DNA-binding activity and
interact with their target sites through interactions with cellular
DNA-binding proteins, the binding sites analysed in this study
represent sites at which the EBNAs indirectly interact with DNA.
ChIP-seq was carried out using an EBNA 2-specific monoclonal
antibody and compared to ChIP-seq data generated in our
laboratory using an anti-EBNA 3C polyclonal antibody that we
found also independently precipitates EBNA 3A and 3B, albeit at
a lower efficiency (Figure S2) [37] (ChIP-seq data are available
through GEO Series accession number GSE47629). Our analysis
identified 21,605 significant EBNA 2 binding sites and 7044
significant EBNA 3 binding sites in the human genome indicating
that overall EBNA 3A, 3B and 3C proteins target fewer regulatory
regions than EBNA 2. Our previous analysis of the human
genome binding profile of the EBNA 3 proteins in the Mutu III
cell line and recent analysis of EBNA 2 binding in an LCL
carrying an EBNA 3B-deleted virus by Zhao et al revealed that
only a small proportion of binding sites for these factors are
proximal to gene transcription start sites (TSS) [17,37]. Consistent
with these observations, our analysis revealed that 75% of EBNA 2
sites and 84% of EBNA 3 sites were located distal (.4 kb) to TSSs
(Figure 1A and B). Examination of the distances between genes
and the closest binding sites for EBNA 2 and EBNA 3 proteins
revealed that the closest EBNA 3 binding site was most often 10–
50 kb from TSSs. In contrast, the closest EBNA 2 binding sites
were found both proximal and distal to gene TSSs with similar
frequency (Figure 1C). In conclusion, EBNA 2 and 3 proteins
generally target distal regulatory elements rather than promoter
sequences, with this being most apparent for the EBNA 3s.
We next considered how EBNA 2 and 3 binding patterns might
be related. Comparing binding we detected considerable overlap
in the regulatory elements targeted by these proteins, with 25% of
all highly significant sites identified bound by both EBNA 2 and
the EBNA 3s (Figure 1D). Surprisingly, EBNA 3-only sites
constituted only 8% of the sites identified in this analysis
(Figure 1D). These data point to a key role of EBNA 3 proteins
in the coregulation of cellular gene expression with EBNA 2.
We next sought to identify the genes targeted by EBNA 2 and 3
proteins via the binding sites we had mapped. Looking at binding
sites located within 2 kb of a gene TSS, we found that EBNA 2
was associated with 3554 genes and EBNA 3 with 664 genes,
consistent with the smaller number of EBNA 3 binding sites in the
genome. Comparing genes with EBNA 3 binding sites within 2 kb
of the TSS with genes within 2 kb of EBNA 2 binding sites
revealed that 62% (412/664) of EBNA 3 proximal target genes
were also bound by EBNA 2 (Figure 1E). In fact for 411 of these
412 genes, the proximal EBNA 2 and 3 binding sites were
overlapping. Using more relaxed criteria to associate a binding site
with a gene, we also identified the genes that were closest to a
binding site irrespective of the distance from the site. Using this
approach, we found that 80% (3157/3937) of genes closest to an
EBNA 3 binding site were also the closest genes to an EBNA 2
binding site. Taken together our analysis indicates that EBNA 2
and 3 proteins generally target the same cellular genes and that a
major role of the EBNA 3 proteins is in the co-regulation of genes
with EBNA 2.
Comparison with gene expression array data links gene
targeting with regulation
To obtain information on whether the potential gene targets we
had identified through binding site analysis were regulated by
EBNA 2 or EBNA 3 proteins, we examined data available from
our own and other published gene expression array studies
[11,32,37–39,56–59,61–62]. We found that 46% (299/654) of
EBNA 2-regulated genes identified in these studies had EBNA 2
binding sites within 2 kb of a TSS. In contrast only 8% (199/2601)
of documented EBNA 3-regulated genes had promoter-proximal
EBNA 3 protein binding sites, likely reflecting the fact that gene
regulation by the EBNA 3s is predominantly mediated via distal
elements. Consistent with distal regulation of gene expression by
the EBNA 3 proteins, the proportion of previously identified
EBNA 3-regulated genes associated with an EBNA 3 binding site
increased to 31% (802/2601) when we considered genes that were
closest to a binding site, irrespective of the distance [32,37–39,61–
62]. Concordantly, the proportion of previously identified EBNA
2-regulated target genes associated with an EBNA 2 binding site
increased to 60% (393/654) when genes any distance from a
binding site were included in the analysis.
EBNA 2 and EBNA 3 binding sites colocalize with histone
modifications found at regulatory regions
To obtain information on the chromatin landscape at sites
bound by EBNA 2 and the EBNA 3 proteins, we examined histone
modifications mapped by ENCODE in the EBV-immortalised
LCL GM12878 at the locations of the top 1000 most significant
EBNA binding sites mapped in Mutu III BL cells. The GM12878
LCL expresses the same set of EBV latent genes expressed in Mutu
III cells (Figure S1) and although there may be some variation in
chromatin landscape between BL cells and LCLs, this LCL
represents a useful proxy. We found that the majority of EBNA 2
binding sites could be broadly grouped into three clusters defined
by high levels of acetylated lysine 27 on Histone H3 (H3K27ac)
and the presence of mono-methylated lysine 4 on Histone H3
(H3K4me1), a profile indicative of active enhancers [63]
(Figure 2A). The remaining EBNA 2 binding sites displayed the
characteristic H3K4me1 enhancer mark, but lacked significant
levels of H3K27ac, a profile indicative of poised/inactive
enhancers [64] (Figure 2A). These poised EBNA 2 enhancer sites
lacked detectable levels of H3K27me3 that can be found in
association with some classes of poised enhancers [65]. Plotting
average histone modification ChIP-seq signals across the top 1000
EBNA 2 binding sites confirmed enrichment of H3K4me1 and
H3K27ac and the absence of H3K27me3 (Figure S3).
A proportion of the top 1000 EBNA 3 binding sites in the
human genome also displayed the characteristics of active
enhancers (H3K4me1+, H3K27ac+) (Figure 2B). It is noteworthy
that these active EBNA 3 enhancer sites were also associated with
high-levels of EBNA 2 binding (Figure 2B). The remaining EBNA
3 binding sites displayed the characteristics of poised enhancers
(H3K4me1+, H3K27ac2) (Figure 2B). Plotting average histone
modification ChIP-seq signals across the top 1000 EBNA 3
binding sites confirmed enrichment of H3K4me1 and H3K27ac
and the absence of H3K27me3, similar to that observed for EBNA
2 binding sites (Figure S4). The chromatin landscape at EBNA 3
binding sites is consistent with the function of these proteins as
both repressors and activators of transcription, but it is interesting
that our analysis did not detect any colocalization of the
H3K27me3 mark, or the K27 methyltransferase EZH2 that has
been associated with EBNA 3-mediated gene repression
[37,48,53,55] (Figure 2B and S4). However, H3K27me3 is often
EBV Transcription Factors Control Enhancer Looping
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broadly spread over promoter and gene bodies and the lack of
H3K27me3 at EBNA 3 binding sites may be consistent with our
recent observation that the repression of ADAM 28 and
ADAMDEC1 by EBNA 3C via an intergenic enhancer was
associated with larger increases in H3K27me3 within the genes
than at the actual binding site [37].
EBNA 2 and 3 binding sites are also bound by B-cell
specific transcription factors
To determine whether specific cellular transcription factor
binding motifs were enriched at sites bound by EBNA 2, 3A, 3B
and 3C we performed unbiased motif searching using the top 300
most significant EBNA binding sites. We found that EBNA 2 sites
were enriched for RBP-Jk and EBF1 motifs and that binding sites
for the EBNA 3s were enriched for PU.1 motifs (Figure 2C and D).
All shared sites were enriched for PU.1 and EBF1 motifs
(Figure 2E). These data provide support for a role for RBP-Jk
and PU.1 in EBNA 2 and EBNA 3C gene targeting in vivo and
corroborate recent reports of enrichment of EBF1 motifs at EBNA
2 binding sites in LCLs, implicating EBF1 in EBNA 2 targeting or
binding stabilization [12–15,17,42–45].
We next examined transcription factor binding at EBNA 2 and
EBNA 3 binding sites using recently published RBP-Jk ChIP-seq
data from the EBV-immortalised LCL, IB4 [17] and ENCODE
GM12878 ChIP-seq data available for numerous transcription
factors and regulators. As expected, the top 1000 EBNA 2 binding
sites mapped in Mutu III cells were also extensively bound by both
EBNA 2 and the EBNA 2 targeting partner RBP-Jk in IB4 cells.
EBNA 2 binding sites were however also bound by a plethora of
transcription factors expressed in B cells that have not been
previously implicated in EBNA 2 targeting, including BATF,
Bcl11a, Bcl3, IRF4, PAX5, SP1 and TCF12 (Figure S5). Binding
of the histone acetyl transferase p300, a co-activator characteris-
tically associated with enhancers, is also evident at EBNA 2 sites.
Plotting average ChIP-seq signals across EBNA 2 binding sites
confirmed the binding of BATF, Bcl11a, Bcl3, IRF4, PAX5, SP1,
TCF12 and p300 (Figure S6). These plots also detected association
of the EBNA 2 binding protein PU.1 [15] with EBNA 2 binding
Figure 1. Analysis of ChIP-seq data for EBNA 2 and EBNA 3 proteins. (A) Pie chart showing the distribution of all significant binding sites for
EBNA 2 relative to gene TSSs. (B) Distribution of EBNA 3 family binding sites. (C) The frequency of EBNA 2 or EBNA 3 protein binding sites plotted as
distance from the TSS of the closest gene. (D) Pie chart showing the proportion of sites identified for EBNA 2 and EBNA 3 family proteins that are
shared or unique. (E) Comparison of genes closest to EBNA 2 binding sites with genes closest to EBNA 3 binding sites for sites within 2 kb of a TSS. (F)
Comparison of genes closest to an EBNA 2 or EBNA 3 binding site located any distance from a gene TSS.
doi:10.1371/journal.ppat.1003636.g001
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sites. Interestingly, EBF1 ChIP-seq signals were high across EBNA
2 binding sites (Figure S6) consistent with the presence of EBF1
binding motifs at EBNA 2 sites (Figure 2C and E) and recent
studies implicating EBF1 in EBNA 2 transcriptional regulation
[17]. Our analysis revealed that the top 1000 EBNA 3 binding
sites were also extensively bound by the same set of factors bound
at EBNA 2 sites including RBP-Jk, BATF, Bcl11a, Bcl3, IRF4,
PAX5, SP1, TCF12, PU.1, EBF1 and p300 (Figures S5 and S7).
In summary, our co-association analyses detect the binding of
multiple transcription factors at EBNA binding sites, with the
binding of known targeting partners indistinguishable from that of
a plethora of other transcription factors. These results are
consistent with genome-wide ChIP-seq analyses by ENCODE
that detect extensive context and cell-type specific co-association of
multiple transcription factors with the same regulatory sites [66].
This is likely to reflect the accessibility of open chromatin at the
binding site and protein-protein interactions between transcription
factors. As a result, although our motif searching confirmed a
potential role for EBF1 in EBNA 2 targeting, examination of the
binding of particular transcription factors at EBNA binding sites
through co-association analysis does not appear to be useful for the
identification of the specific factors that may involved in targeting
or stabilising the binding of EBNA 2 and 3 proteins to cellular
DNA regulatory elements.
Investigating the role of co-incident EBNA 2 and 3
protein binding at key gene loci
Since our analysis of EBNA 2 and 3 binding had revealed a
large number of shared binding sites, we set out to investigate the
nature of this shared binding and its role in the control of
epigenetic reprogramming by EBV. We carried out follow-up
studies on three cellular genes (CTBP2, WEE1 and ITGAL) with
highly significant common binding sites for EBNA 2 and EBNA 3
proteins with ChIP-seq peak heights of .10 sequence reads per
million background subtracted reads. These genes are involved in
regulating key processes relevant to cellular transformation
including transcription repression, cell-cycle and cell adhesion
and activation. C-terminal binding proteins (CtBPs) encoded by
the closely-related genes CTBP2 and CTBP1 mediate transcrip-
tional repression of a number of key tumour suppressor genes [67].
CtBPs play a key role in EBV transformation; CtBP binding by
EBNA 3A and EBNA 3C is required for the epigenetic repression
of p16INK4a in infected cells [53]. WEE1 encodes a cell-cycle
kinase and negative regulator of CDK1 that controls the transition
Figure 2. Colocalization of histone modifications and transcription factor binding at EBNA 2 and 3 binding sites. (A) Heatmap of EBNA
2, EBNA 3 and histone modification ChIP-seq signals at the top 1000 EBNA 2 binding sites. EBNA 2 and 3 ChIP-seq data from Mutu III BL cells was
aggregated with ENCODE histone modification ChIP-seq data from the GM12878 LCL using hierarchical clustering. Each window displays the ChIP-
seq signal 2/+ 1 kb around the EBNA 2 binding site midpoint. Clusters of active enhancers (H3K4me1+, H3K27ac+) and poised enhancers
(H3K4me1+, H3K27ac2) are indicated. (B) Heatmap of EBNA 3, EBNA 2 and histone modification ChIP-seq signals at the top 1000 EBNA 3 binding
sites. (C) Position weight matrix and TF consensus prediction generated from unbiased motif searching using the top 300 EBNA 2 binding sites.
Numbers show the p-value for site enrichment. (D) Position weight matrix derived from motif searching using the top 300 EBNA 3 family sites. (E)
Position weight matrix for motif searching using all shared sites.
doi:10.1371/journal.ppat.1003636.g002
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from G2 into mitosis, a process that is deregulated at multiple
potential levels by EBV [68–70]. The B-cell adhesion protein
integrin alpha L encoded by the ITGAL gene forms part of the
heterodimeric activation antigen, LFA-1, that is upregulated in
EBV-infected cells [71]. These three genes also provide represen-
tative examples of co-incident binding sites at intragenic (CTBP2)
and downstream (WEE1) long-range locations and at a gene
promoter (ITGAL). CTBP2 and WEE1 represent novel EBV
cellular gene targets identified in our study as the closest genes to
EBNA 2 and 3 binding sites; ITGAL was previously identified as a
gene repressed by EBNA 3B and 3C by White et al in microarray
studies of BL cells infected with recombinant knock-out EBVs
[38]. Expression of the LFA-1 heterodimer composed of integrin
alpha L (CD11a) and beta 2 integrin has also been shown to be
upregulated by the EBV membrane protein, LMP1 [72].
EBNA 3A, 3B and 3C bind the C-terminal binding protein
2 (CTBP2) enhancer
A single co-incident binding site for EBNA 2 and EBNA 3
proteins was mapped in the second intron of CTBP2, 95 kb
downstream from the TSS (Figure 3). To confirm our ChIP-seq
data we carried out ChIP-QPCR using EBNA 2-specific
antibodies in the Mutu III cells used for ChIP-seq analysis using
sets of primers designed to amplify the binding site, adjacent
control regions and the peptidylprolyl isomerase 1 (PPIA) control
gene, which is not bound or regulated by the EBNAs. This analysis
confirmed that EBNA 2 bound specifically to the CTBP2
intragenic site in vivo (Figure 3B). Since our ChIP-seq analysis
was carried out using an antibody that precipitated all three EBNA
3 proteins, we also carried out ChIP-QPCR in Mutu III cells to
examine the binding of EBNA 3A, 3B and 3C proteins
individually using anti-EBNA 3A, anti-EBNA 3B and anti-EBNA
3C antibodies that we verified do not cross-react with other family
members (Figure S8). Our results demonstrated that EBNA 3A,
3B and 3C were all able to associate with the CTBP2 site in Mutu
III cells (Figure 3B–E). We also extended our ChIP-QPCR
analysis to examine binding of EBNA 2, 3A, 3B and 3C to the
CTBP2 site in an EBV-immortalized LCL to investigate any
potential cell-type specific differences in binding. As in Mutu III
cells, we found that EBNA 2, 3A, 3B and 3C were all able to
associate with the CTBP2 intragenic site in an LCL (Figure 3F–I).
Previous expression microarray analyses have not identified
CTBP2 as an EBNA 2, 3A, 3B or 3C-regulated gene. However,
examination of microarray data from a study carried out by Hertle
et al [32] (re-analysed by Dr R. White and colleagues and available
at www.epstein-barrvirus.org.uk) using sets of LCLs infected with
wild-type or EBNA 3A mutant EBV (Figure S9) revealed that
expression of CTBP2 was upregulated in LCLs infected with
EBNA 3A knock-out (KO) EBV. These data implicate EBNA 3A
as a repressor of CTBP2 transcription. QPCR analysis of CTBP2
mRNA levels in these EBNA 3A KO LCLs confirmed that loss of
EBNA 3A leads to a dramatic upregulation of CTBP2 transcript
levels (Figure 3J). The predominant isoform of CTBP2 expressed in
these cells initiates from the third most distal promoter (Figure
S10). We also found that CTBP2 mRNA levels were higher in a
latency I BL cell line expressing only EBNA 1 (Mutu I) compared
to Mutu III cells, the latency III derivative of this cell line that
expresses all EBV latent proteins (Figure 3J). To investigate the
specific effects of EBNA 3B on CTBP2 mRNA expression we
analysed pairs of LCLs infected with wild-type or EBNA 3B KO
EBV (Figure S9). Consistent with our observations in EBNA 3A
KO LCLs, we found that a lack of EBNA 3B expression also lead
to an increase in CTBP2 transcript levels (Figure 3K). Taken
together these data strongly implicate EBNA 3A and 3B binding at
the CTBP2 locus in transcriptional repression of this gene.
Interestingly, during our analysis we found that CTBP2 expression
was cell-line specific; significant levels of CTBP2 transcripts were
not detectable in a number of cell lines previously used in
expression microarray studies by White et al [38]. These include a
set of wild-type and EBNA 3B knock-out LCLs and the BL31 and
BL2 cells used to generate a series of EBNA 3A, 3B or 3C knock-
out cell lines [38,54]. As a result we have been unable to analyse
the effects of EBNA 3C gene knock-out on CTBP2mRNA levels as
the currently available EBNA 3C knock-out cell lines were
generated in the BL31 or BL2 background [54].
To investigate any potential effects of EBNA 2 on CTBP2
expression that may not have been detected in previous expression
studies, we examined CTBP2 mRNA levels in LCLs expressing a
conditionally active estrogen receptor-EBNA 2 fusion protein
(ER/EB 2.5) [3]. Our analysis did not detect any significant effect
of the loss of EBNA 2 function on CTBP2 transcript levels
(Figure 3L). Our data therefore correlate EBNA 3A and 3B
binding at the CTBP2 site with the repression of CTBP2
transcription by these factors, but do not detect any effect of loss
of EBNA 2 on CTBP2 mRNA levels in the presence of the EBNA
3s.
EBNA 3 proteins repress CTBP2 transcription by
preventing enhancer-promoter looping
To determine the role of the long-range CTBP2 intragenic
EBNA 2, 3A, 3B and 3C binding site in controlling CTBP2
transcription, we performed chromosome conformation capture
analysis [73] to examine potential interactions between this site
and the CTBP2 promoter through the formation of chromatin
loops. Following digestion of cross-linked chromatin using an
enzyme that cleaves intervening DNA, enhancer and promoter
regions can be ligated together at low dilution using this technique
only if these elements are in close spatial proximity (Figure 4A).
We found that PCR amplification products using primers
spanning the CTBP2 enhancer-promoter ligation junction could
not be detected in LCLs generated from wild-type EBV where all
EBNAs are expressed, but were readily detectable in EBNA 3A
knock-out LCLs (Figure 4B). These data indicate that enhancer-
promoter chromatin loops form in the absence of EBNA 3A but
not in wild-type infected cells. Loop formation correlated with
increased CTBP2 transcription in EBNA 3A knock-out LCLs
indicating that looping at the CTBP2 locus is associated with active
transcription (Figure 3J). These data are consistent with a model
where EBNA 3A represses CTBP2 transcription by preventing the
formation of chromatin loops that mediate gene activation.
Concordantly, chromosome conformation capture experiments
in LCLs expressing a conditionally active ER-EBNA 2 demon-
strated that CTBP2 promoter-enhancer interactions were absent in
these cells irrespective of whether EBNA 2 was functional (+/2 b-
estradiol) (Figure 4C and D) presumably as a result of the
dominant binding and prevention of looping by the EBNA 3
proteins.
To directly examine whether EBNA 2 and 3 proteins can
associate with the CTBP2 enhancer at the same time or compete
for binding, we carried out re-ChIP analysis. Primary precip-
itation of chromatin was carried out using an EBNA 2-specific
antibody and immunoprecipitated protein-DNA complexes were
then eluted from the bead matrix and a second round of
precipitation carried out using EBNA 2, 3A, 3B or 3C-specific
antibodies (Figure 4E). Our analysis detected re-precipitation of
EBNA 2 bound to the CTBP2 enhancer using EBNA 2-specific
antibodies as expected, but EBNA 3A, 3B and 3C were not
precipitated from EBNA 2-DNA complexes, despite the fact that
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Figure 3. EBNA 2, 3A, 3B and 3C binding at the CTBP2 locus in EBV-infected cells. (A) The number of EBNA 2 (green) and EBNA 3 (red)
sequencing reads from immunoprecipitated Mutu III DNA are plotted per million background-subtracted total reads and aligned with the human
genome. The direction of gene transcription is indicated by the red arrow. GM12878 LCL H3K27ac ChIP-seq data from ENCODE are shown at the
bottom of the panel. Panels B-E show ChIP-QPCR carried out in Mutu III cells and panels F-I show data from the PER253 B95.8 LCL. Precipitated DNA
was analysed using primer sets located at the binding site (set B) or regions on either side of the binding site (sets A and C). Primers spanning the
transcription start site of the cellular gene encoding peptidylprolyl isomerase A (PPIA) that is not regulated or bound by the EBNAs provide a
background binding control (indicated by dotted lines). (B) and (F) ChIP using anti-EBNA 2 antibodies. (C) and (G) ChIP using anti-EBNA 3A antibodies.
(D) and (H) ChIP using anti-EBNA 3B antibodies. (E) and (I) ChIP using anti-EBNA 3C antibodies. Percentage input signals, after subtraction of no
antibody controls, are shown as the mean +/2 range of two independent experiments. (J) Q-PCR analysis of CTBP2 transcript levels using cDNA from
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they can be re-precipitated with the antibodies used (Figure 4F–
H). Reciprocal re-ChIP experiments carried out using EBNA
3A, 3B or 3C antibodies in the first round and EBNA 2
antibodies in the second round confirmed that EBNA 2 could
not be precipitated from EBNA 3-DNA complexes (Figure S11).
Our results therefore indicate that EBNA 3A, 3B and 3C do not
bind the CTBP2 enhancer at the same time as EBNA 2. Binding
profiles obtained in ChIP therefore represent independent
binding of EBNA 2 or EBNA 3 proteins to this site in different
cells within the total cell population assayed. In summary, our
results are consistent with CTBP2 transcriptional repression by
EBNA 3 proteins via competitive binding at the CTBP2
intragenic enhancer (Figure 4D).
Cell-type specific differential binding of EBNA 3 proteins
to two downstream distal enhancers at the WEE1 locus
ChIP-seq detected binding of EBNA 2 and 3 proteins to co-
incident binding sites located in two clusters +27 kb and +39 to
44 kb downstream from the WEE1 TSS (Figure 5). The first
cluster, enhancer 1 (+27 kb) has two distinct binding sites for
EBNA 3 proteins (sites 1 and 2), with EBNA 2 binding detected
predominantly at the most distal of these two sites (site 2). The
second cluster, enhancer 2 (+39 to 44 kb) contains 3 binding sites
(sites 3–5), with the highest binding signal for EBNA 3 proteins
detected at the most distal site (site 5). Both clusters of EBNA 2 and
3 binding sites coincide with peaks of H3K27ac detected in
ENCODE ChIP-seq experiments in the GM12878 LCL indicat-
ing that the binding sites are located within active gene regulatory
regions (Figure 5).
ChIP-QPCR analysis confirmed EBNA 2 binding to all five sites
in both Mutu III cells and an LCL (Figure 5). Consistent with
ChIP-seq data, we detected the highest levels of EBNA 2 binding
at site 2 in both cell lines (Figure 5B and F). EBNA 3A and 3B
binding atWEE1 was low-level, with only small amounts of EBNA
3A binding at sites 4 and 5 in LCLs and weak EBNA 3B binding at
sites 1 and 2 in Mutu III cells (Figure 5C, D, G and H). In
contrast, EBNA 3C bound specific WEE1 enhancer sites at levels
similar to that detected at CTBP2, although there were cell-type
specific differences in the binding profile (Figure 5E and I). EBNA
3C bound predominantly at site 5 in Mutu III cells, but at both
sites 4 and 5 in an LCL (Figure 5E and I).
Like CTBP2, WEE1 had not previously been documented as a
gene regulated by EBNA 2 or EBNA 3 proteins. However,
examination of microarray data obtained by White et al [38] from
BL31 cells infected with a series of EBNA 3 knock-out viruses
provided evidence of repressive effects of EBNA 3C (but not
EBNA 3A and 3B) on WEE1 mRNA expression (www.epstein-
barrvirus.org.uk). QPCR analysis of these BL31 cell lines
confirmed that WEE1 transcript levels were modestly but
significantly increased in cells infected with EBNA 3C knock-out
EBV compared to cells infected with wild-type EBV or revertant
viruses (Figure 5J). Examination of microarray data obtained by
White et al [38] and Hertle et al [32] using EBNA 3B and EBNA
3A knock-out LCLs respectively, confirmed that EBNA 3A and
EBNA 3B had no detectable effect on WEE1 mRNA levels. Our
data are therefore consistent with EBNA 3C binding to the most
distal enhancer region (enhancer 2) downstream of WEE1 playing
a dominant role in the repression ofWEE1 transcription. The low-
level association of EBNA 3A and 3B at WEE1 enhancer sites
however, does not detectably affect WEE1 mRNA levels in BL
cells or LCLs.
To address the potential contribution of EBNA 2 in the
regulation of WEE1 transcription we examined WEE1 mRNA
expression in BL31 cells infected with an EBNA 2 knock-out virus
and in LCLs expressing conditionally active EBNA 2. Our analysis
revealed that WEE1 mRNA levels are reduced in the absence of
EBNA 2 activity, implicating EBNA 2 in the positive regulation of
WEE1 transcription (Figure 5K and L). Taken together our data
indicate that the level of WEE1 transcription in EBV-infected cells
is likely to be determined by a balance between gene repression by
EBNA 3C that is counteracted by EBNA 2.
EBNA 3C represses WEE1 transcription by directing the
formation of enhancer-promoter loops
To examine potential looping interactions between the down-
stream WEE1 enhancers and the WEE1 promoter and their
regulation by EBNA 2 and 3C, we performed chromosome
conformation capture analysis. In contrast to the situation at the
CTBP2 locus, our results indicated that looping interactions at
WEE1 were associated with transcriptional repression. Looping
between both enhancer 1 (sites 1 and 2) and enhancer 2 (sites 3, 4
and 5) and the promoter was not detectable in parental EBV
negative BL31 cells, but was detectable in wild-type EBV infected
BL31 cells where WEE1 expression is repressed (Figure 5J).
Consistent with the key role played by EBNA 3C in transcriptional
repression of WEE1, looping interactions were absent in BL31
cells infected with EBNA 3C knock-out viruses indicating that
EBNA 3C is required to maintain enhancer-promoter looping
(Figure 6B).
The dominant role of EBNA 3C binding in mediating
transcriptional repression of WEE1 via chromatin looping was
supported by our observations that looping interactions were
maintained in BL31 cells infected with EBNA 2 knock-out viruses
and in an ER-EBNA 2 LCL when EBNA 2 function was inhibited
through b-estradiol withdrawal (Figure 6C and D). Taken together
these data support a model where EBNA 3C binding to a
downstream enhancer element directs chromatin looping with the
WEE1 promoter to facilitate transcriptional repression (Figure 6E).
Given that loss of EBNA 2 decreases WEE1 transcription
(Figure 5J), EBNA 2 may compete with EBNA 3C for binding
to WEE1 enhancer sites and limit EBNA 3C-mediated repression
in infected cells. It is likely that the semi-quantitative chromosome
conformation capture assay is not able to detect the increased
looping that may occur in the absence of EBNA 2. Consistent with
competitive binding of EBNA 2 and 3 proteins and our
observations at the CTBP2 locus, re-ChIP experiments did not
detect co-association of EBNA 2 and 3C at WEE1 enhancer 2
(Figure 6F and G and S11).
wild-type LCLs (wt1, 2 and 3) and LCLs established from EBNA 3A knock-out viruses (mtB1, B2 and B3) in two different donor backgrounds (D2 and
D3). Transcript levels were normalised to GAPDH levels and expressed relative to the level in D2 wt1 cells. (K) Q-PCR analysis of CTBP2 transcript levels
using cDNA from wild-type LCLs infected with B95.8 virus (wt) and EBNA 3B knock-out LCLs (KO) in two different donor backgrounds (PER142 and
PER253). Transcript levels were normalised to GAPDH levels and expressed relative to the level in wt cells for each donor. (L) Q-PCR analysis of CTBP2
transcript levels using cDNA from the ER/EB 2.5 LCL expressing EBNA 2 that is active in the presence of b-estradiol (+ est) and inactive in the absence
of b-estradiol (2est). Cells were incubated in b-estradiol-free media for 4 days prior to re-addition of b-estradiol or DMSO control for 6 or 17 hrs.
Transcript levels were normalised to GAPDH levels and expressed relative to the level in the absence of b-estradiol for each time course. All cDNA
results (J–L) show the mean 2/+ range of two independent QPCR reactions each performed in duplicate.
doi:10.1371/journal.ppat.1003636.g003
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Cell-type specific differential binding of EBNA 3 proteins
to the ITGAL promoter
At ITGAL a series of three co-incident binding sites for EBNA 2
and EBNA 3 proteins are located in a 2 kb region encompassing
the TSS that coincides with a peak of LCL H3K27ac (Figure 7).
Consistent with ChIP-seq analysis, ChIP-QPCR experiments
confirmed that EBNA 2 bound predominantly at site 3 in both
BL cells and an LCL (Figure 7B and F). Interestingly, when we
examined individual binding of EBNA 3 proteins to these
promoter sites, we found that EBNA 3B also bound at site 3 in
both BL cells and LCLs (Figure 4D and H), but there was no
significant binding of EBNA 3A in either cell line, despite our
ability to detect significant levels of EBNA 3A binding at the
CTBP2 locus in the same ChIP samples (Figure 7C and G). We
Figure 4. The influence of EBNA 2 and 3A on chromosome looping at the CTBP2 locus. (A) Diagram (not to scale) showing the EcoR1
restriction fragments at the CTBP2 locus that encompass the promoter (P), enhancer (E) and an intervening control region (con). The arrow indicates
the direction of transcription. (B) Chromosome conformation analysis in LCLs infected with wild-type or EBNA 3A knock-out EBV using primer pairs
that amplify across promoter-enhancer or promoter-control ligation junctions. Positive controls show PCR amplification from control digestion and
ligation reactions carried out using PCR-amplified DNA fragments encompassing the promoter, enhancer and control regions. (C). Chromosome
conformation capture analysis in the ER-EB 2.5 LCL expressing EBNA 2 that is active in the presence of b-estradiol (+ est) and inactive in the absence
of b-estradiol (2est). (D) Model for the control of chromatin looping by EBNA 2 and 3 proteins at CTBP2. (E) Re-ChIP analysis using anti-EBNA 2
antibodies in the first round of ChIP followed by a second round of ChIP in absence of antibody or using anti-EBNA 2, EBNA 3A, EBNA 3B or EBNA 3C
antibodies. Results show mean percentage primary input 2/+ range of two independent Q-PCR reactions from a representative experiment. (F)
Control re-ChIP analysis using anti-EBNA 3A antibodies in the first round followed by re-precipitation in the absence of antibody or using anti-EBNA
3A antibodies. (G) Control re-ChIP analysis using anti-EBNA 3B antibodies in the first round followed by re-precipitation in the absence of antibody or
using anti-EBNA 3B antibodies. (H) Control re-ChIP analysis using anti-EBNA 3C antibodies in the first round followed by re-precipitation in the
absence of antibody or using anti-EBNA 3C antibodies.
doi:10.1371/journal.ppat.1003636.g004
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Figure 5. EBNA 2 and EBNA 3 protein binding at the WEE1 locus in EBV infected cells. (A) EBNA 2 (green) and EBNA 3 (red) sequencing
reads at the WEE1 locus (displayed as described in Figure 3). Panels B–E show ChIP-QPCR carried out in Mutu III cells and panels F–I show data from
the PER253 B95.8 LCL. Precipitated DNA was analysed using primer sets located at the binding sites (sets B, D, F, H and J) or regions adjacent to the
binding sites (sets A, C, E, G and I). Binding signals at the CTBP2 binding site in the same ChIP experiments are shown as a positive control and primers
spanning the transcription start site of the cellular gene PPIA provide a background binding control (indicated by dotted lines). (B) and (F) ChIP using
anti-EBNA 2 antibodies. (C) and (G) ChIP using anti-EBNA 3A antibodies. (D) and (H) ChIP using anti-EBNA 3B antibodies. (E) and (I) ChIP using anti-
EBNA 3C antibodies. Percentage input signals, after subtraction of no antibody controls, are shown as the mean 2/+ range of two independent ChIP
experiments. (J) Q-PCR analysis ofWEE1 transcript levels using cDNA from BL31 parental cells and BL31 cells infected with wild-type recombinant EBV
(wtBac-2 and 3), EBNA 3C knock-out EBV (3C KO-3 and 6) or EBNA 3C revertant EBV (3Crev-2 and 4). Transcript levels were normalised to GAPDH levels
and expressed relative to the level in parental BL31 cells. * indicates a p-value of ,0.01 (students t-test) compared to the wtBac-2 cell line. (K) Q-PCR
analysis of WEE1 transcript levels using cDNA from the ER/EB 2.5 LCL expressing EBNA 2 that is active in the presence of b-estradiol (+ est) and
inactive in the absence of b-estradiol (2est). Cells were incubated in b-estradiol-free media for 4 days prior to re-addition of b-estradiol for 6 or 17 hrs.
Transcript levels were normalised to GAPDH levels and expressed relative to the level in the absence of b-estradiol. All cDNA results (J–L) show the
mean 2/+ standard deviation of three independent QPCR analyses from two independent cDNA preparations.
doi:10.1371/journal.ppat.1003636.g005
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Figure 6. The influence of EBNA 2 and 3C on chromosome looping at the WEE1 locus. (A) Diagram (not to scale) showing the EcoR1
restriction fragments at the WEE1 locus that encompass the promoter (P), two downstream enhancers (E1 and E2) and an intervening control region
(con). The arrow indicates the direction of transcription. (B) Chromosome conformation analysis in BL31 parental cells and BL31 cells infected with
wild-type recombinant EBV (wtBac-2), EBNA 3C knock-out EBV (3CKO-3) or EBNA 3C revertant EBV (3Crev-4) using primer pairs that amplify across
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also found that although EBNA 3C bound site 3 in Mutu III cells
at levels significantly above the background level detected at a
control gene, there was no significant EBNA 3C binding in LCLs
(Figure 7E and I). Remarkably, the differential and cell-type
specific targeting of the ITGAL promoter by EBNA 3 family
members we detected is entirely consistent with the documented
effects of individual EBNA 3 proteins on ITGAL expression in
these different cell backgrounds. Consistent with our observations
in the Mutu III BL cell line, the White et al BL31 study [38]
detected significant and reproducible increases in ITGAL expres-
sion in cell lines infected with EBNA 3B or EBNA 3C knock-out
EBV, but not EBNA 3A knock-out EBV, compared to cells
infected with wild-type EBV. EBNA 3B knock-out BL31 cells
displayed a 3.09-fold (p-value: 2.77E-05) increase in ITGAL
expression vs wild-type infected BL31 cells and EBNA 3C
knock-out BL31 cells displayed a 2.72-fold increase (p-value:
1.09E-04) [38]. Interestingly, examination of microarray data
from the White et al [38] and Hertle et al [32] LCL studies (www.
epstein-barrvirus.org.uk) revealed a role for EBNA 3B, but not
EBNA 3A in the repression of ITGAL expression in LCLs. These
data are entirely consistent with our ChIP QPCR analysis where
binding of EBNA 3B was detected in LCLs in the absence of any
significant EBNA 3A or EBNA 3C binding (Figure 7G, H and I).
We confirmed the repressive effects of EBNA 3B on ITGAL
expression in LCLs using an additional independent set of wild-
type and EBNA 3B knock-out cell lines (Figure 8A). Thus ITGAL is
an EBNA 3B and 3C-repressed gene in BL cells and an EBNA 3B
only-repressed gene in LCLs. Since EBNA 3A appears to play no
role in ITGAL regulation, importantly our data demonstrate that it
is the gene and cell-type specific binding of different members of
the EBNA 3 protein family that determines the requirement for
each EBNA 3 protein in the regulation of specific cellular genes.
Since ITGAL is upregulated by EBV LMP1 [72], a direct target
gene of EBNA 2 that is not expressed in the absence of EBNA 2,
the effects of LMP1 and EBNA 2 on ITGAL expression cannot be
separated using cells which lack functional EBNA 2. We therefore
examined the regulation of the ITGAL promoter by EBNA 2 using
ITGAL promoter-reporter constructs containing the 2 kb region
encompassing all 3 binding sites. Transient transfection assays
demonstrated that EBNA 2 activated the ITGAL promoter up to
5-fold (Figure 8B). The co-expression of EBNA 3A, 3B or 3C
resulted in the inhibition of EBNA 2 activation (Figure 8B). These
data are consistent with a model where EBNA 3 proteins can
compete with EBNA 2 for binding sites in the ITGAL promoter to
repress ITGAL transcription. It therefore appears that although
EBNA 3A and EBNA 3C (in LCLs) do not bind the ITGAL
promoter site significantly in vivo, these proteins are able to bind
and compete with EBNA 2 for binding to this site when expressed
at high levels in reporter assays. Competitive binding of EBNA 2
and 3 proteins at the ITGAL promoter was also supported by re-
ChIP analysis in the Mutu III BL cell line, where we detected no
simultaneous binding of EBNA 2 with EBNA 3B or EBNA 3C
(Figure 8C–E and Figure S11).
EBNA 3 proteins also differentially bind EBNA 3-only
promoter and enhancer sites
Our observations that the regulation of ITGAL and WEE1
expression by members of the EBNA 3 family was directed by the
differential binding of subsets of these proteins to binding sites
shared by EBNA 2 led us to investigate whether this was also the
case at genes regulated by EBNA 3-only sites. The BCL2L11 (Bim)
gene is known to be transcriptionally repressed by EBNA 3A and
EBNA 3C, but not EBNA 3B [54] and recent studies using an
epitope-tagged form of EBNA 3C have detected binding of EBNA
3C over a broad region from 23648 to +631 bps around the
BCL2L11 TSS [48]. Although the peak binding signal of this tagged
EBNA 3C in BL31 cells was detected with primer sets located2247
to2147 bps upstream of the BCL2L11 TSS, our ChIP-seq analysis
fine-mapped significant EBNA 3 binding sites between +87 to
+921 bps downstream of the BCL2L11 TSS. ChIP-QPCR analysis
of the binding of individual EBNA 3A, 3B and 3C proteins to this
site revealed that only EBNA 3A and 3C bind at significant levels in
both the Mutu III BL and an LCL, consistent with the regulation of
BCL2L11 expression by these two proteins (Figure 9B–G).We found
that the peak of binding of EBNA 3A and 3C was detected by ChIP-
QPCR using primer sets located +540 to +630 downstream from
the TSS (set B) (Figure 9B–G).
We also examined differential binding of EBNA 3A, 3B and 3C
to an EBNA 3-only distal regulatory element located between the
ADAMDEC1 and ADAM28 genes that we have previously
characterised [37]. We previously demonstrated that repression
of ADAM28 and ADAMDEC1 transcription through H3K27me3
could be mediated through the action of EBNA 3C alone and
detected EBNA 3C binding to this intergenic element in EBNA
3C-expressing cells [37]. Microarray studies have also implicated
EBNA 3A in ADAMDEC1 repression in LCLs and BL cells and in
ADAM28 repression in LCLs [32,38]. Consistent with a role for
both EBNA 3A and EBNA 3C in the repression of ADAMDEC1
transcription, we detected binding of EBNA 3A and EBNA 3C,
but not EBNA 3B to the ADAM intergenic element in both BL
cells and an LCL (Figure 10). Our data therefore indicate that the
specificity of cellular gene regulation by members of the EBNA 3
family is directed by the differential binding of different family
members to both unique EBNA 3 binding sites and binding sites
shared with EBNA 2.
EBNA 3C binding at the ADAM intergenic site directs
transcriptional repression via chromatin looping
To determine whether binding of EBNA 3 proteins to unique
rather than shared sites was also able to direct chromatin looping,
we used chromosome conformation capture to detect potential
interactions between the ADAM intergenic EBNA 3 binding site
promoter-enhancer or promoter-control ligation junctions. Positive controls show PCR amplification from control digestion and ligation reactions
carried out using PCR-amplified DNA fragments encompassing the promoter and enhancers. (C) Chromosome conformation analysis in BL31 parental
cells and BL31 cells infected with wild-type recombinant EBV (wtBac-2) or EBNA 2 KO EBV. (D) Chromosome conformation capture analysis in the ER-
EB 2.5 LCL expressing EBNA 2 that is active in the presence of b-estradiol (+ est) and inactive in the absence of b-estradiol (2est). (E) Model for the
control of chromatin looping by EBNA 2 and 3 proteins at WEE1. (F) Re-ChIP analysis in Mutu III cells using anti-EBNA 2 antibodies in the first round of
ChIP followed by a second round of ChIP in absence of antibody or using anti-EBNA 2 or EBNA 3A, 3B or 3C antibodies. Primers at peak 5 in enhancer
2 were used for analysis. Results show mean percentage primary input 2/+ range of two independent Q-PCR reactions from a representative
experiment. (G) Control re-ChIP analysis using anti-EBNA 3C antibodies in the first round followed by re-precipitation in the absence of antibody or
using anti-EBNA 3C antibodies.
doi:10.1371/journal.ppat.1003636.g006
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Figure 7. EBNA 2 and EBNA 3 protein binding at the ITGAL promoter in EBV-infected cells. (A) EBNA 2 (green) and EBNA 3 (red)
sequencing reads from immunoprecipitated Mutu III DNA plotted as in Figure 3. Panels B–E show ChIP-QPCR carried out in Mutu III cells and panels
F–I show data from the PER253 B95.8 LCL. Precipitated DNA was analysed using primer sets located at the binding sites (sets B, D, and F) or regions
adjacent to the binding sites (sets A, C, and E). Binding signals at the CTBP2 binding site in the same ChIP experiments are shown as a positive control
and primers spanning the transcription start site of the cellular gene PPIA provide a background binding control (indicated by dotted lines). (B) and
(F) ChIP using anti-EBNA 2 antibodies. (C) and (G) ChIP using anti-EBNA 3A antibodies. (D) and (H) ChIP using anti-EBNA 3B antibodies. (E) and (I) ChIP
using anti-EBNA 3C antibodies. Percentage input signals, after subtraction of no antibody controls, are shown as the mean 2/+ range of two
independent ChIP experiments.
doi:10.1371/journal.ppat.1003636.g007
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Figure 8. The Effect of EBNA 2 and 3 proteins on ITGAL expression. (A) Q-PCR analysis of ITGAL transcript levels using cDNA from wild-type
LCLs infected with B95.8 virus (wt) and EBNA 3B knock-out LCLs (KO) in two different donor backgrounds (PER142 and PER253). Transcript levels were
normalised to GAPDH levels and expressed relative to the level in wt cells for each donor. Results show the mean 2/+ range of two independent
QPCR reactions each performed in duplicate. (B) Luciferase reporter assays carried out in DG75 cells transiently transfected with 2 mg of the control
vector pGL3 basic, an ITGAL promoter-luciferase reporter (pGL3 ITGALp) or the EBV C promoter reporter (pCp1425GL2) (right panel) in the absence or
presence of 10 or 20 mg of EBNA 2, 3A, 3B or 3C expressing constructs. Firefly luciferase signals were normalised to Renilla luciferase signals from the
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and both the ADAMDEC1 and ADAM28 promoters in an EBNA
3C-expressing B-cell line. Our analysis revealed that the intergenic
enhancer was in close proximity to both the ADAM28 promoter
and the ADAMDEC1 promoter only in cells expressing EBNA 3C
(BJAB E3C-3) and not in control cells (BJAB pz1) (Figure 11).
These data indicate that EBNA 3C binding represses ADAMDEC1
and ADAM28 transcription by promoting juxtaposition of the
intergenic binding element with the two distal ADAM gene
promoters to facilitate H3K27me3 via the recruitment of
polycomb repressor complexes. Although our data demonstrate
that EBNA 3C is able to promote chromatin looping and gene
repression alone, the binding of EBNA 3A to the intergenic site
and the fact that the absence of EBNA 3A expression leads to
increased ADAMDEC1 and ADAM28 expression also implicates
EBNA 3A in the repression of ADAM gene transcription.
Discussion
The findings described here provide important mechanistic
insights into two key outstanding questions in EBV biology that
impact on our understanding of fundamental transcriptional
control mechanisms and host-cell reprogramming by viruses (i)
how are long-range cellular enhancers hijacked by EBV to direct
epigenetic reprogramming? (ii) what is the basis for gene-specific
and cell background specific gene deregulation by the EBNA 3
family of transcription factors? We have discovered that (i) EBV-
encoded transcriptional activators and repressors modulate
enhancer-promoter loop formation at cellular genes to regulate
their transcription and (ii) transcriptional deregulation is controlled
in a gene and cell-background specific manner through differential
binding of subsets of EBV transcription factors to cellular
regulatory elements. These discoveries provide important infor-
mation on the mechanisms through which EBV transcriptionally
and epigenetically reprogrammes the host cell. Our studies have
also identified two new target genes repressed by EBNA 3 proteins
in infected cells (WEE1 and CTBP2) and identified additional
EBV-directed mechanisms for controlling expression of the LFA-1
subunit encoded by the ITGAL gene. Transcriptional deregulation
of these genes may play important roles in facilitating immortal-
ization and viral persistence.
Recent studies using ChIP-seq technology have revealed that
enhancer elements are more widespread than originally thought
and may constitute 10% of the human genome [74]. Perturbation
of enhancer function appears to play a key role in cancer
development since an increasing number of single nucleotide
polymorphisms at cancer risk loci map to enhancer elements and
are associated with gene deregulation [75–78]. Our analysis has
revealed that enhancer elements are also targeted and deregulated
by a tumour virus to promote cellular gene deregulation during
transformation, providing further evidence of a key role for the
modulation of chromatin architecture during tumourigenesis.
CTBP2
Vertebrate genomes contain two genes, CTBP1 and CTBP2,
that encode the closely-related proteins CtBP1 and CtBP2,
collectively referred to as CtBP. CtBP was first identified as a
binding partner of the adenovirus oncoprotein E1A [79–80] and
promotes cell survival, invasion and metastatic potential through
transcriptional repression of a diverse range of tumour suppressors
including E-cadherin, PTEN and p16INK4a (reviewed in [67]).
Interestingly, CtBP appears to play a key role in EBV-mediated
transformation through interactions with EBNA 3A and 3C
[46,50]. Mutation of the CtBP binding motifs in EBNA 3A and 3C
removes their ability to function as co-operative oncogenes in
transformation assays and delays outgrowth of immortalized cells
on primary infection [46,50,53].The epigenetic repression of
p16INK4a by EBNA 3A and 3C via CtBP has recently been shown
to be a crucial step in the EBV transformation process [53,62].
Although our data reveal that CTBP2 expression is repressed by
the EBNA 3 proteins, there are no binding sites for EBNA 2 or 3
proteins at the CTBP1 locus indicating that CTBP2 is uniquely
targeted. The control of total levels of CtBP levels by modulating
CtBP2 expression may therefore be important in controlling EBV
transformation, but it is also possible that CtBP2 could be
performing functions distinct from CtBP1 in the cell that may limit
immortalization. Recent reports have in fact identified a unique
role for CtBP2 as a transcriptional activator [81].
Although we have shown that EBNA 3A, 3B and 3C bind the
CTBP2 intragenic enhancer, our analysis of mRNA expression in
EBNA 3 knock-out cell lines to date has only implicated EBNA 3A
and EBNA 3B in the repression of CTBP2 transcription, due to the
lack of CTBP2 expression in the EBNA 3C knock-out cell-lines
available. The role of EBNA 3C in the regulation of CTBP2
expression therefore remains to be tested. Perhaps surprisingly,
analysis of cell-lines conditionally expressing EBNA 2 also failed to
detect differential regulation of CTBP2 mRNA levels despite the
binding of EBNA 2 to the CTBP2 enhancer. The EBNA 2 ChIP-
seq signal at CTBP2 is at least half of the signal at the WEE1 and
ITGAL sites so it is possible that the affinity of EBNA 2 binding at
the CTBP2 site is lower, making competition for binding with the
EBNA 3 proteins less efficient. In EBV-infected cells the binding of
the EBNA 3 proteins may therefore be dominant leading to
effective inhibition of promoter-enhancer looping.
WEE1
The WEE1 gene encodes the Wee1 kinase, a key negative
regulator of the G2/M cell-cycle transition [82]. Wee1 inactivates
the mitotic cyclin-dependent kinase CDK1 during interphase
through phosphorylation on tyrosine 15. This residue is subse-
quently dephosphorylated by the CDC25 phosphatase at the end
of G2, triggering entry into mitosis. EBV infection results in the
deregulation of the cell-cycle, with EBNA 3C playing a key role in
overriding G1/S, G2/M and mitotic checkpoints through
numerous potential mechanisms that include transcriptional
repression and the regulation of protein stability [83–84].
Disruption of the G2/M checkpoint may be mediated through
effects on the Chk2 kinase and we have recently described
upregulation of an activator of CDK1, RGC-32, in EBV-infected
cells [69,85]. Although Wee1 has not previously been implicated
in EBV-mediated cell-cycle disruption, a recent microarray study
co-transfected control plasmid pRL-TK (1 mg). Results show the mean 2/+ standard deviation of 3 independent experiments and are expressed
relative to the pGL3 basic signal (left panel) or the Cp1425GL2 signal (right panel) in the absence of EBNA 2. Western blot analysis of EBNA 2, 3A, 3B
and 3C expression levels in transfected cells. Each set of blots was also probed for actin as a loading control. (C) Re-ChIP analysis in Mutu III cells using
anti-EBNA 2 antibodies in the first round of ChIP followed by a second round of ChIP in absence of antibody or using anti-EBNA 2, EBNA 3B or EBNA
3C antibodies. Primers at peak 3 were used for analysis. Results show mean percentage primary input2/+ range of two independent Q-PCR reactions
from a representative experiment. (D) Control re-ChIP analysis using anti-EBNA 3B antibodies in the first round followed by re-precipitation in the
absence of antibody or using anti-EBNA 3B antibodies. (E) Control re-ChIP analysis using anti-EBNA 3C antibodies in the first round followed by re-
precipitation in the absence of antibody or using anti-EBNA 3C antibodies.
doi:10.1371/journal.ppat.1003636.g008
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identified WEE1 as the fourth most regulated gene in the ‘cell
proliferation’ gene ontology category in newly EBV-infected
hyperproliferating B-cells [86]. WEE1 was upregulated in these
infected proliferating cells and subsequently downregulated in the
resulting immortalized LCLs, although levels remained higher
than in uninfected cells. This pattern of expression was also
observed for a key set of DNA damage response genes [86].
Interestingly, EBNA 3C was shown to be required for the
repression of the DNA damage response induced in response to
EBV infection, thus facilitating the outgrowth of permanently
Figure 9. EBNA 3 protein binding at the BCL2L11 promoter in EBV-infected cells. (A) EBNA 3 sequencing reads from immunoprecipitated
Mutu III DNA plotted as in Figure 3. Panels B–D show ChIP-QPCR carried out in Mutu III cells and panels F–G show data from the PER253 B95.8 LCL.
Precipitated DNA was analysed using primer sets located at the binding site (set B) or regions on either side of the binding site (sets A and C). Binding
signals at the CTBP2 binding site in the same ChIP experiments are shown as a positive control and primers spanning the transcription start site of the
cellular gene PPIA provide a background binding control (indicated by dotted lines). (B) and (E) ChIP using anti-EBNA 3A antibodies. (C) and (F) ChIP
using anti-EBNA 3B antibodies. (D) and (G) ChIP using anti-EBNA 3C antibodies. Percentage input signals, after subtraction of no antibody controls,
are shown as the mean 2/+ range of two independent experiments.
doi:10.1371/journal.ppat.1003636.g009
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proliferating cells [86]. Our data demonstrating that EBNA 3C
can repress WEE1 expression, an effect counteracted by EBNA 2,
may now also implicate EBNA 3C in suppressing the negative
effects of WEE1 on the G2/M checkpoint during the outgrowth of
EBV- immortalized cells.
ITGAL
ITGAL encodes alpha L integrin (CD11a) that together with b2
integrin (CD18) forms the heterodimeric integrin, LFA-1 that
mediates homotypic and heterotypic adhesion via binding to
Intracellular cell adhesion molecules (ICAM) 1–3 [87]. LFA-1
plays an important role in the recruitment of immune cells to sites
of infection and promotes T-cell migration and the activation of
intracellular signalling cascades [88–89]. LFA-1 is upregulated on
infection of primary B-cells by EBV along with ICAM1, LFA-3
and a number of B-cell activation molecules, mimicking the B-cell
activation phenotype observed on exposure to antigen or mitogens
[90]. Expression of the EBV-encoded constitutively active cell-
surface receptor LMP1 alone in EBV negative B-cells is sufficient
to induce LFA-1 expression on the surface of these cells,
implicating LMP1-directed signalling in the activation of ITGAL
expression [72,91].
Our analysis has now revealed that EBNA 2 and a cell-type
specific subset of EBNA 3 proteins bind to the ITGAL promoter in
vivo implicating the co-ordinated activities of multiple EBV-
encoded factors in the regulation of ITGAL expression in EBV-
infected cells. EBNA 2 and EBNA 3 proteins appear to bind to this
site competitively and EBNA 2 activation is inhibited by the
presence of any one of the EBNA3s in reporter assays. Since in vivo
only EBNA 3B binds the ITGAL promoter in LCLs and EBNA 3B
and EBNA 3C bind in BLs, our reporter assays indicate that when
overexpressed all EBNA 3s have the potential to interfere with
EBNA 2 activation of the ITGAL promoter, presumably through
competitive binding. It is therefore likely that the differential in vivo
binding of the EBNA3s to the ITGAL promoter is regulated by the
chromatin context and the binding of cellular transcription factors.
Interestingly, previous analysis of B-cell lines stably expressing
EBNA 2 or EBNA 3C alone reported no change in ITGAL (LFA-1)
expression [72,92]. The effects of EBNA 2 and 3C on the ITGAL
promoter may therefore be context-specific, perhaps depending on
the expression of cellular DNA targeting factors and the co-
ordinated actions of multiple EBV-encoded latent proteins in
infected cells. Consistent with this possibility and similar to WEE1,
ITGAL expression is upregulated in the early stages of proliferation
following EBV infection with expression subsequently reduced in
the resulting LCLs [86]. Thus ITGAL expression may be regulated
by LMP1 and the EBNAs in a temporal fashion during infection.
Mechanism of EBNA 3-mediated repression
Since the anti-EBNA 3C antibody we used for ChIP-seq
analysis independently precipitates EBNA 3A and EBNA 3B, our
analysis has mapped binding sites for all 3 EBNA 3 proteins in the
human genome. Although these sites would be expected to be
enriched for EBNA 3C binding sites since the efficiency of EBNA
3A and 3B precipitation by the antibody is lower (Figure S2), we
have successfully confirmed EBNA 3A and EBNA 3B binding sites
Figure 10. EBNA 3 protein binding at the ADAM28/ADAMDEC1 intergenic enhancer in EBV-infected cells. ChIP-QPCR carried out in Mutu
III cells (A–C) and the PER253 B95.8 LCL (D–F). Precipitated DNA was analysed using primer sets located at the centre of the binding site (set B) or the
edges of the binding site (sets A and C). Binding signals at the CTBP2 binding site in the same ChIP experiments are shown as a positive control and
primers spanning the transcription start site of the cellular gene PPIA provide a background binding control (indicated by dotted lines). (A) and (D)
ChIP using anti-EBNA 3A antibodies. (B) and (E) ChIP using anti-EBNA 3B antibodies. (C) and (F) ChIP using anti-EBNA 3C antibodies.
doi:10.1371/journal.ppat.1003636.g010
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at multiple loci by Q-PCR. Our data thus provide a useful starting
point for the study of gene regulation by all three EBNA 3
proteins.
Interestingly, our studies on shared EBNA 2 and EBNA 3
binding sites support a role for EBNA 3 proteins in the repression
of all three EBNA target genes we investigated (CTBP2, WEE1
and ITGAL). EBNA 2 appears to compete for binding to these sites
limiting EBNA 3-mediated repression to different extents depend-
ing on the gene locus. Thus at CTBP2, the EBNA 3 proteins
appear to inhibit gene activation via the prevention of looping
even in the presence of EBNA 2, with loss of EBNA 2 activity
having little effect on CTBP2 gene expression. At WEE1 however,
despite the establishment of chromatin loops that appear to
mediate transcriptional repression by EBNA 3C in the presence of
Figure 11. The influence of EBNA 3C on chromosome looping at the ADAM28/ADAMDEC1 locus. (A) Diagram (not to scale) showing the
HindIII restriction fragments around the ADAM28 locus that encompass the promoter (P), the ADAM enhancer (E, located downstream of ADAM28)
and two intervening control regions (con1 and con2). The arrow indicates the direction of transcription. (B) Chromosome conformation analysis of the
ADAM28 locus in the pz1 control BJAB cell line (2) and the E3C-3 stable EBNA 3C expressing cell line (+) using primer pairs that amplify across
promoter-enhancer or promoter-control ligation junctions. Positive controls show PCR amplification from control digestion and ligation reactions
carried out using PCR-amplified DNA fragments encompassing the promoter, enhancer and control regions. (C) Diagram (not to scale) showing the
AciI restriction fragments around the ADAMDEC1 locus that encompass the promoter (P), the ADAM enhancer (E, located upstream of ADAMDEC1)
and an intervening control region (con). The arrow indicates the direction of transcription. (D) Chromosome conformation analysis of the ADAMDEC1
locus in the pz1 control BJAB cell line (2) and the E3C-3 stable EBNA 3C expressing cell line (+) using primer pairs that amplify across promoter-
enhancer or promoter-control ligation junctions. Positive controls show PCR amplification from control digestion and ligation reactions carried out
using PCR-amplified DNA fragments encompassing the promoter, enhancer and control region.
doi:10.1371/journal.ppat.1003636.g011
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EBNA 2, loss of EBNA 2 results in decreased WEE1 expression
indicating that EBNA 2 does limit EBNA 3C-mediated repression
to some extent.
Our analysis also demonstrates that repression of gene
transcription via binding of EBNA 3 proteins to enhancer
elements results from the modulation of chromatin architecture
in two different ways. At the CTBP2 locus, EBNA 3 proteins
prevent the formation of chromatin loops that presumably activate
the CTBP2 promoter and at WEE1, EBNA 3C is required for the
formation of loops associated with transcriptional repression. At an
EBNA 3-only binding site at the ADAM28/ADAMDEC1 locus
EBNA 3C again promoted transcriptional repression via enhanc-
er-promoter looping. Interestingly, consistent with our observa-
tions at CTBP2, the Drosophila Snail repressor protein has recently
been shown to inhibit transcription via the prevention of enhancer
looping (anti-looping) [93]. However, we are unaware of any
previous reports of the establishment of chromatin loops by
transcriptional repressor proteins that facilitate the repression of
target genes. Our results therefore provide important new insights
into the mechanism of action of transcriptional repressors.
Our previous analysis correlated binding of EBNA 3C to the
intergenic distal binding site between the ADAM28 and ADAM-
DEC1 genes with increases in the polycomb repressor complex-
associated H3K27me3 mark across the genes and EBNA 3C-
mediated repression of mRNA expression [37]. Consistent with
the repressive effects of EBNA 3A on ADAM28 and ADAMDEC1
expression [32,38], our results now indicate that EBNA 3A co-
operates in ADAM gene repression via association with this
intergenic binding site. Thus repression directed via enhancer
looping from EBNA 3A and EBNA 3C binding sites to gene
promoters appears to be mediated in an analogous fashion to the
H3K27me3-associated repression of genes that are targeted via
promoter binding sites (BCL2L11 and p16INK4a) [53,55]. It will be
interesting to determine whether EBNA 3C-directed looping at the
shared EBNA 2 and 3C WEE1 enhancer binding sites also directs
transcriptional repression via increases in H3K27me3, or through
other potential effects on the recruitment or phosphorylation of
RNA polymerase II.
Specificity of EBNA 3A, 3B and 3C targeting and gene
regulation
Our studies have uncovered the molecular basis for the
regulation of overlapping and distinct sets of cellular genes by
different members of the EBNA 3 protein family. This is mediated
by gene-specific, and in some cases cell-type specific, differential
binding of EBNA 3A, 3B and 3C to gene regulatory elements.
This differential binding is evident at both promoter and enhancer
binding sites, although we have yet to identify the mechanism
through which this differential binding is achieved.
Since EBNA 3 proteins do not bind DNA directly, binding
specificity is likely to be directed through interactions with specific
B-cell DNA-binding proteins. Unfortunately, analysis of EN-
CODE ChIP-seq binding data for a vast array of transcription
factors was not useful in identifying the specific players involved in
targeting EBNA 2 or 3 proteins to DNA. This analysis revealed
that a plethora of B-cell transcription factors associate with EBNA
2 and 3 binding sites in LCLs consistent with an extensive network
of protein-protein interactions between transcription factors at
open chromatin sites. However, using motif searching we found
that EBNA 3 binding sites were enriched for PU.1 (Spi-1) binding
motifs highlighting an important role for PU.1 in cellular gene
targeting by EBNA 3 proteins in vivo. PU.1 has been previously
implicated in EBNA 3C-mediated co-activation of the LMP1
promoter with EBNA 2 via Spi-1/Spi-B sites [45] and indeed we
also found that EBNA 2 and 3 shared sites were enriched for
PU.1/Spi-1 binding motifs. Since our ChIP-seq analysis identified
EBNA 3A, 3B and 3C binding sites it will be important to
determine whether EBNA 3A and 3B can direct cellular gene
regulation via PU.1 or whether enrichment of PU.1 binding motifs
was detected in our study as a result of its enrichment at EBNA 3C
binding sites only. It is of interest that EBNA 3C has recently been
shown to bind and stabilise interferon regulatory factor 4 (IRF4)
[94], a PU.1 binding partner. Dimerization between the DNA
binding domains of PU.1 and IRF4 plays a key role in regulation
via adjacent PU.1 and IRF4 motifs, such as those found in the
mouse immunoglobulin l light chain gene enhancer [95].
Although the PU.1-dependent co-activation of the LMP1
promoter by EBNA 3C was not dependent on an adjacent IRF4
binding site [45], it is possible that IRF4 may play a role in
directing EBNA 3C-mediated cellular gene regulation, potentially
in co-operation with PU.1. It is clear however, that the
identification of the factors that direct the specificity of binding
of EBNA 3A, 3B and 3C will necessitate a multi-pronged
approach using a combination of proteomics to identify chroma-
tin-associated binding partners and analysis of the genome-wide
binding profiles of the individual EBNA 3 proteins and any co-
associated transcription factor binding.
Although our data indicate that EBNA 2 is not bound to shared
sites at the same time as EBNA 3 proteins, we have not been able
to definitively determine whether the sets of EBNA 3 proteins
bound to the same binding site are associated with the site
simultaneously using the currently available antibodies. Recent
studies have reported an interaction between EBNA 3A and 3C
that could potentially explain the high degree of co-operativity
between these two proteins in the regulation of cellular genes if
these two proteins are bound to gene regulatory elements as a
complex [48]. However, we have identified regulatory sites that
are bound by EBNA 3C and not significantly by EBNA 3A at
WEE1 and ITGAL, so these two proteins do not always appear to
be present at the same site. Examination of the individual binding
profiles of EBNA 3A, 3B and 3C and further re-ChIP analysis
using new reagents will be required to determine whether these
proteins do indeed bind simultaneously.
Given that the remaining EBV-encoded nuclear proteins,
EBNA-1 and EBNA-LP also function as transcriptional regulators
and multiple EBNA-1 binding sites in the human genome have
been mapped in BL cells [96], it will be important in future studies
to build up a composite picture of how the EBNAs target the
human genome to direct cellular reprogramming by mapping
shared and unique binding sites in the same cell background and
addressing the combined impact of these factors on cellular gene
expression. This will enable us to fully explore the way in which
EBV deregulates cellular gene expression to further our under-
standing of cellular transformation.
Methods
Cell lines
The EBV-negative BL cell line DG75 and the EBV-positive
latency III BL cell line Mutu III expressing all EBV latent proteins
have been described previously [60,97]. The EBV negative BL31
Burkitt’s lymphoma cell lines infected with wild-type recombinant
EBV Bacmids or EBNA 2 or EBNA 3C knock-out and revertant
Bacmids have been described previously and were kindly provided
by Dr R. White and Prof M. Allday [54,98]. The control (pz1) and
EBNA 3C-expressing (E3C-3) stable transfectants of the EBV-
negative B-cell lymphoma cell line BJAB were previously
described [72]. The sets of wild-type (wt1, wt2, wt3) and EBNA
EBV Transcription Factors Control Enhancer Looping
PLOS Pathogens | www.plospathogens.org 19 September 2013 | Volume 9 | Issue 9 | e1003636
3A knock-out LCLs (mtB1, mtB2, mtB3) have been previously
described and were generated from B-cells derived from two
different donors (donor 2 (D2) and donor 3 (D3)) using
recombinant viruses [32]. The sets of wild-type and EBNA 3B
knock-out LCLs were kindly provided by Dr H. Long and were
generated using B-cells from two different donors (PER253 and
PER142) infected with either wild-type B95.8 EBV derived from
the marmoset B95.8 cell line or EBNA 3B-knock-out recombinant
virus [99]. The LCL expressing conditionally active ER-EBNA 2
(ER/EB 2.5) has also been described previously [3]. For b-
estradiol withdrawal and add back experiments ER/EB 2.5 cells
were incubated in the absence of b-estradiol for 4 days and 1 mM
b-estradiol was re-added for 6 or 17 hrs prior to cell harvest. All
cell lines were routinely passaged twice-weekly and cultured using
the conditions previously described for each line.
Chromatin immunoprecipitation
For ChIP-sequencing, EBNA 2 and EBNA 3 proteins were
immunoprecipitated from 306106 cross-linked Mutu III cells as
described previously [37]. EBNA 3 proteins were precipitated using
sheep polyclonal anti-EBNA 3C antibodies (Abcam, ab16128) that
we found also independently precipitate EBNA 3A and 3B as a
result of cross-reactivity (Figure S2). EBNA 2 was precipitated using
a 6-fold scale-up of previously described methods using 48 mg
EBNA 2-specific mouse monoclonal antibody (PE2, gift from Prof
M. Rowe), followed by an additional incubation with 81 mg rabbit
anti-mouse antibodies (Dako) [100–101].
For ChIP-Quantitative PCR (ChIP-QPCR) EBNA 2 was
immunoprecipiated from 56106 cross-linked cells using the PE2
monoclonal antibody as described previously [100–101]. EBNA
3A ChIP was carried out using 8 mg sheep polyclonal antibodies
(Ex-alpha Biologicals, Inc., F115P) and EBNA 3B ChIP was
performed using 8 mg sheep polyclonal antibodies (Ex-alpha
Biologicals, Inc., F120P) following the protocol previously
described for polyclonal antibodies [101]. EBNA 3C ChIP was
carried out using 8 mg of E3cD8 monoclonal antibody [102] (gift
from Prof M. Rowe) followed by an additional incubation with
13.5 mg rabbit anti-mouse antibodies (Dako).
Re-ChIP was performed essentially as previously described
[101] using the antibody quantities described above and BSA-
blocked protein A agarose beads (Merck).
Library preparation, sequencing and data analysis
EBNA 2 ChIP and input DNA was used to generate sequencing
libraries that were then subjected to 35 bp single-end read
sequencing with an Illumina Genome Analyzer IIx as described
previously [37]. ChIP-seq data analysis was carried out as
previously described [37] with initial significant peaks of binding
identified with MACS (p,1027) [103]. The distance between
binding sites and RefSeq gene TSS were calculated and the
nearest gene TSS identified. 200 bp regions centred on peak
positions were considered as binding sites for further analysis. The
distance between binding sites and RefSeq gene TSS were
calculated and the nearest gene TSS identified. In unique versus
shared site comparisons, for a site to be considered bound by one
factor only, the p-value for binding had to be below 10-7 for that
factor and above 10-2 for the other factor. For a site to be
considered bound by both factors, the p-value for binding had to
be below 10-6 for each and the two 200 bp binding regions also
had to overlap by at least 100 bp.
Quantitative real-time PCR
For transcript analysis, total RNA was prepared using
Trireagent (Sigma) and purified using RNeasy columns (Qiagen).
cDNA was then synthesised using the ImProm-II reverse
transcription system and random oligonucleotides (Promega). Real
time PCR was carried out using an Applied Biosystems
StepOnePlus PCR machine and the primers indicated in Table
S1. Real time PCR reactions contained 3 ml of DNA, 7.5 ml of
GoTaq qPCR mastermix (Promega) and 2.25 pmoles of each
primer in a total volume of 15 ml. DNA was amplified by heating
samples to 95uC for 10 minutes followed by 40 cycles of 95uC for
15 seconds and 60uC for 1 minute prior to dissociation curve
analysis. Serial dilutions of cDNA or input DNA (for ChIP) were
used to generate standard curves for each primer set. For ChIP
analysis, the no antibody control signal was subtracted from the
percentage input signal derived from the standard curve.
Chromosome conformation capture
Chromosome conformation capture assays were carried out
essentially as described previously [104]. Cells were passed
through a 70 mm filter to obtain a single cell preparation. 16107
cells were then fixed in 1% formaldehyde in the presence of 10%
FCS for 10 mins at room temperature. The reaction was
quenched with 0.125M glycine, and cells were collected by
centrifugation at 230 g at 4uC. The pellet was resuspended in
0.5 ml cold lysis buffer (10 mM Tris-HCl, pH 7.7; 10 mM NaCl;
5 mM MgCl2; 0.1 mM EGTA) with freshly added complete
protease inhibitors (Roche) and lysed on ice for 10 mins. The
nuclei were collected by centrifugation at 400 g for 10 min at 4uC,
resuspended in 0.5 ml of 1.2X Buffer 4 (New England Biolabs)
containing 0.3% SDS and incubated for 1 hr at 37uC while
shaking at 900 rpm. Triton X-100 was then added to the nuclei to
give a final concentration of 2% and the samples incubated for
1 hr at 37uC with shaking. 400 U EcoRI-HF, HindIII or AciI (New
England Biolabs) were added to the nuclei and the samples
incubated at 37uC overnight with shaking. The digestion reaction
was stopped by addition of sodium dodecyl sulphate to a final
concentration of 1.6% and incubation at 65uC for 25 mins with
shaking. The sample was then diluted 10-fold with 1.15X ligation
Buffer (New England Biolabs) containing 1% Triton X-100 and
then incubated for 1 hr at 37uC with shaking. 100 U T4 DNA
ligase (New England Biolabs) were added to the sample and the
reaction was incubated at 16uC for 4 hrs and then 30 mins at
room temperature. 300 mg of Proteinase K (Roche) were added to
the sample and the reaction incubated at 65uC overnight. RNA
was removed by incubation with 300 mg of RNAse for 45 mins at
37uC. Following two rounds of phenol-chloroform extraction,
DNA was ethanol precipitated and analysed by PCR using
primers designed to amplify across ligation junctions (Table S1).
As a control for ligation products, genomic DNA regions
covering restriction sites of interest were amplified by PCR,
purified, mixed in equimolar quantities and then digested with
EcoRI-HF, HindIII or AciI (New England Biolabs) for 1.5 hours.
Following heat inactivation at 65uC, the digested PCR products
were incubated with 10 U T4 DNA-ligase (New England Biolabs)
over a temperature range of 4 to 20uC overnight. The DNA was
purified using the QIAquick Gel Extraction Kit (Qiagen). Purified
positive control DNA was then analysed by PCR using the same
primers used for chromosome conformation capture.
Plasmid construction, transient transfections and
reporter assays
The ITGAL promoter region from 21756 to +174 bp
encompassing all 3 binding sites was amplified from genomic
DNA extracted from an LCL using primers designed to introduce
SacI and HindIII sites at the 59 and 39 end respectively (Table S1)
and cloned into pGL3 basic (Promega). The EBV C promoter
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luciferase reporter construct pCp1425GL2 was described previ-
ously [105].
DG75 cells were transfected by electroporation as described
previously [100]. Cells were transfected with 2 mg pGL3 basic or
pGL3-ITGALp, 1 mg of pRL-TK as a transfection control and 10
or 20 mg of pSG5-2A (expressing EBNA 2), pcDNA3 EBNA 3A,
EBNA 3B or EBNA 3C expressing constructs (gift from Dr A.Bell).
DNA amounts in each transfection were equalized using empty
vector. Cells were harvested after 48 hrs and luciferase assays
performed using the Dual luciferase assay kit (Promega) as
described previously [100] using a Promega Glowmax multi-
dection system.
Immunoblotting
Immunoblotting was carried out as described previously
[100,105] using the following antibodies: anti-EBNA 3C (mouse
monoclonal, E3CA10 [102]), anti-EBNA 3A (sheep polyclonal,
Ex-alpha Biologicals, Inc., F115P), anti-EBNA 3B (sheep poly-
clonal, Ex-alpha Biologicals, Inc., F120P or rabbit polyclonal,
Bioss, bs-4698R), anti-EBNA-LP (Santa Cruz biotechnology, Inc
sc-23537), anti-actin (Sigma), anti-TFIID (TBP) (Santa Cruz
biotechnology, Inc sc-421). EBNA-1 was detected using M.S.
human serum as previously described [101].
Supporting Information
Figure S1 Western blot analysis of EBNA expression in
Mutu III cells and the GM12878 LCL. EBNA 1, 2, 3A, 3B,
3C and -LP expression was detected by western blotting using
whole cell lysates. Blots were probed for actin as a control for
loading.
(PDF)
Figure S2 An EBNA 3C polyclonal antibody indepen-
dently precipitates EBNA 3A and 3B. EBNA 3 proteins were
immunoprecipitated from stable BJAB transfectants expressing
either EBNA 3A (3A-1), EBNA 3B (E3B-2) or EBNA 3C (E3C-3)
under the same conditions used for ChIP but in the absence of
cross-linking treatment. BJAB cell lysates and immunoprecipita-
tions carried out using EBNA 3A (Ex-alpha F115P), 3B (Ex-alpha
F120P) or EBNA 3C (Abcam ab16128) specific antibodies were
analysed by Western blotting using EBNA 3A, EBNA 3B or
EBNA 3C-specific antibodies. The EBNA 3C antibody is able to
independently immunoprecipitate EBNA 3A from cells only
expressing EBNA 3A (top panel) and immunoprecipitate EBNA
3B from cells only expressing EBNA 3B (centre panel) indicating
that it cross-reacts with these proteins. This EBNA 3C antibody
does not however generally cross-react with transcription factors as
TATA box binding protein (TBP) is not precipitated.
(PDF)
Figure S3 Mean histone modification signals at EBNA 2
binding sites. Aggregate plots of the mean EBNA 2 and EBNA
3 ChIP-seq signals at the top 1000 EBNA 2 binding sites in Mutu
III cells compared to ENCODE histone modification ChIP-seq
signals in the GM12878 LCL. Each window displays the ChIP-seq
signal2/+1 kb around the EBNA 2 binding site midpoint. Dips in
the histone modification signal at the binding site midpoint
indicate the expected nucleosome-depleted region.
(PDF)
Figure S4 Mean histone modification signals at EBNA 3
binding sites. Aggregate plots of the mean EBNA 3 and EBNA
2 ChIP-seq signals at the top 1000 EBNA 3 binding sites in Mutu
III cells compared to EBNA 2 and RBP-Jk ChIP-seq signals in the
IB4 LCL [17] and ENCODE transcription factor ChIP-seq signals
in the GM12878 LCL (as in Fig. S3).
(PDF)
Figure S5 EBNA 2 and 3 binding sites are bound by
multiple transcription factors. (A) Heatmap of EBNA 2,
EBNA 3 and transcription factor ChIP-seq signals at the top 1000
EBNA 2 binding sites. EBNA 2 and 3 ChIP-seq data from Mutu
III BL cells was aggregated with published IB4 EBNA 2 and RBP-
Jk ChIP-seq data and ENCODE GM12878 ChIP-seq data for
transcription factors using hierarchical clustering. (B) Heatmap of
EBNA 3, EBNA 3and transcription factor ChIP-seq signals at the
top 1000 EBNA 3 binding sites. Only transcription factors where
significant colocalization with EBNA 2 or 3 sites was observed are
shown.
(PDF)
Figure S6 Mean transcription factor binding signals at
EBNA 2 binding sites. Aggregate plots of the mean EBNA 2
and EBNA 3 ChIP-seq signals at the top 1000 EBNA 2 binding
sites in Mutu III cells compared to EBNA 2 and RBP-Jk ChIP-seq
signals in the IB4 LCL [17] and ENCODE transcription factor
ChIP-seq signals in the GM12878 LCL (as in Fig. S3).
(PDF)
Figure S7 Mean transcription factor binding signals at
EBNA 3 binding sites. Aggregate plots of the mean EBNA 3
and EBNA 2 ChIP-seq signals at the top 1000 EBNA 3 binding
sites in Mutu III cells compared to EBNA 2 and RBP-Jk ChIP-seq
signals in the IB4 LCL [17] and ENCODE transcription factor
ChIP-seq signals in the GM12878 LCL (as in Fig. S3).
(PDF)
Figure S8 Immunoprecipitation using EBNA 3 knock-
out cell lines confirms EBNA 3A, 3B and 3C antibody
specificity. EBNA 3 proteins were immunoprecipitated from
BL31 cells infected with wild-type, EBNA 3A KO, EBNA 3B KO
or EBNA 3C KO viruses under the same conditions used for ChIP
but in the absence of cross-linking treatment. BL31 cell lysates (A,
D and G) and immunoprecipitations carried out using EBNA 3A
(Ex-alpha F115P), 3B (Ex-alpha F120P) or 3C (E3CD8) specific
antibodies were analysed by Western blotting using EBNA 3A (A–
C), EBNA 3B (D–F) or EBNA 3C (G–I)-specific antibodies. The
EBNA 3A-specific antibody precipitates EBNA 3A from cells
infected with wild-type EBV and not EBNA 3A Knock-out EBV
(see panel B lanes 2 and 4) (* indicate the position of non-specific
bands present in IPs even from knock-out cells). The EBNA 3A
antibody does not precipitate EBNA 3B (see panel E lane 4) or
EBNA 3C (panel H lane 4) from EBNA 3A Knock-out cells
demonstrating that is does not cross-react. The EBNA 3B-specific
antibody precipitates EBNA 3B from cells infected with wild-type
EBV and not EBNA 3B Knock-out EBV (see panel B lanes 2 and
6) (* indicate the position of non-specific bands present in IPs even
from knock-out cells). The EBNA 3B antibody does not precipitate
EBNA 3A (panel B lane 6) or EBNA 3C (panel H lane 6) from
EBNA 3B Knock-out cells demonstrating that is does not cross-
react. The EBNA 3C-specific antibody precipitates EBNA 3C
from cells infected with wild-type EBV and not EBNA 3C Knock-
out EBV (see panel I lanes 2 and 4). The EBNA 3C antibody does
not precipitate EBNA 3A (panel C lane 4) or EBNA 3B (panel F
lane 4) from EBNA 3B Knock-out cells demonstrating that is does
not cross-react.
(PDF)
Figure S9 Western blot analysis of EBNA 3A and EBNA
3B knock-out LCLs. (A) Western blot analysis of EBNA 3A
expression in whole cell lysates from wild-type LCLs (wt1, 2 and 3)
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and LCLs established from EBNA 3A knock-out viruses (mtB1, B2
and B3) in two different donor backgrounds (D2 and D3). The blot
was probed for actin as a control for loading. Mutu I and Mutu III
cell lysates serve as negative and positive controls, respectively. (B)
Western blot analysis of EBNA 3B expression in whole cell lysates
from wild-type LCLs infected with B95.8 virus (wt) and EBNA 3B
knock-out LCLs (KO) in the PER142 donor background.
(PDF)
Figure S10 CTBP2 promoter analysis. Transcript-specific
QPCR primers spanning the 6 alternative CTBP2 transcription
start sites displayed in the human genome browser were used to
amplify cDNA from wild-type LCLs (D3wt1) where CTBP2
expression is low and LCLs infected with EBNA 3A Knock-out
LCLs (D3mtB1) where CTBP2 expression is high. Transcripts are
named in order of increasing size as (S1, S2, L1, L2, L3 and L4).
(PDF)
Figure S11 Reciprocal re-ChIP analysis confirms that
EBNA 2 and EBNA 3 proteins do not bind simultaneous-
ly. Re-ChIP analysis in Mutu III cells using anti-EBNA 3
antibodies in the first round of ChIP followed by a second round of
ChIP in the absence of antibody or using anti-EBNA 2 antibodies.
Results show mean percentage primary input 2/+ range of two
independent Q-PCR reactions from a representative experiment.
(A) Re-ChIP analysis at the CTBP2 enhancer using anti-EBNA 3A
antibodies in the first round followed by re-precipitation in the
absence of antibody, using anti-EBNA 3A antibodies or anti-
EBNA 2 antibodies. (B) Re-ChIP analysis at the CTBP2 enhancer
using anti-EBNA 3B antibodies in the first round followed by re-
precipitation in the absence of antibody, using anti-EBNA 3C
antibodies or anti-EBNA 2 antibodies. (C) Re-ChIP analysis at the
CTBP2 enhancer using anti-EBNA 3C antibodies in the first round
followed by re-precipitation in the absence of antibody, using anti-
EBNA 3C antibodies or anti-EBNA 2 antibodies. (D) Re-ChIP
analysis at ITGAL promoter peak 3 using anti-EBNA 3B
antibodies in the first round followed by re-precipitation in the
absence of antibody, using anti-EBNA 3B antibodies or anti-
EBNA 2 antibodies. (E) Re-ChIP analysis at ITGAL promoter peak
3 using anti-EBNA 3C antibodies in the first round followed by re-
precipitation in the absence of antibody, using anti-EBNA 3C
antibodies or anti-EBNA 2 antibodies. (F) Re-ChIP analysis at
WEE1 enhancer 2 using anti-EBNA 3C antibodies in the first
round followed by re-precipitation in the absence of antibody,
using anti-EBNA 3C antibodies or anti-EBNA 2 antibodies.
(PDF)
Table S1 Primers used for chromosome conformation
capture, cloning and Q-PCR analysis.
(PDF)
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